化学
淀粉样前体蛋白
酶
组织蛋白酶
蛋白酵素
酶抑制剂
阿尔茨海默病
组织蛋白酶D
衍生工具(金融)
组织蛋白酶B
寡肽
药理学
生物化学
立体化学
肽
疾病
内科学
医学
金融经济学
经济
作者
Jack D. Scott,Sarah W. Li,Andrew P. J. Brunskill,Xia Chen,Kathleen Cox,Jared N. Cumming,Mark S. Forman,Eric J. Gilbert,Robert A. Hodgson,Lynn A. Hyde,Qin Jiang,Ulrich Iserloh,Irina Kazakevich,Reshma Kuvelkar,Hong Mei,J. Wayne Meredith,Jeffrey Misiaszek,Peter Orth,Lana M. Rossiter,Meagan Slater
标识
DOI:10.1021/acs.jmedchem.6b00307
摘要
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates and CSF Aβ levels in humans. In this annotation, we describe the discovery of 3, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core as well as aspects of its preclinical and Phase 1 clinical characterization.
科研通智能强力驱动
Strongly Powered by AbleSci AI